2024年11月22日
Chemical genetics involves the substitution of a gatekeeper residue with an amino acid containing a different side chain at the target locus. Here, we have generated a mutant parasite containing a hypomorphic allele of cdpk1 and identified compensatory pathways adopted by the parasite in the mutant background.
Drug resistance is a major challenge in combating malaria. Our study aims to identify compensatory pathways in malaria parasites containing hypomorphic allele of essential protein kinases. Targeting two kinases simultaneously may be a better strategy that avoids developing drug resistance against individual kinases.
Gene editing using CRISPR-Cas9 has profoundly benefited malaria research and has been instrumental performing allelic exchanges, endogenous tagging, conditional knockout, and knockdown of target gene. The molecular mechanism of drug resistance, understanding target gene function and study of host parasite interaction can now be studied with greater ease. The current experimental challenges include heterologous protein expression in E.coli due to the high richness of the plasmodium genome.
Additionally, of target effect of CRISPR-Cas9 complicated data interpretation and led to erroneous results. Low transcription efficiency with the malaria parasite increases the time required for generating the desired genetic modification. Our findings suggests that targeting a single kinase in the malaria parasite may lead to compensatory over expression of other kinases.
This raises new question about the potential for adaptive resistance and whether dual kinase inhibition could effectively prevent such adaptation, opening avenues for the combination therapeutic strategies. In the future, our laboratory will target other essential protein kinases of malaria parasites using chemical genetics. Transcriptional rewiring in the mutant parasites will help in identifying compensatory pathways that may be simultaneously targeted to prevent development of drug resistance against individual kinases.
本研究探讨了具有必需蛋白激酶功能低下等位基因的疟原虫中的代偿性通路。该研究强调了双重激酶抑制作为克服药物耐药性策略的潜力。
疟疾寄生虫在激酶抑制后通过代偿性通路激活而产生的适应性耐药,为抗疟药物研发带来了严峻挑战。深入理解这些代偿机制有助于更准确地进行靶点验证,并指导双靶点策略的设计,从而降低耐药风险。该策略直接影响以激酶为靶向的治疗药物在早期发现阶段的关键决策点及研发管线的优先排序。
这种化学生物学方法可融入从早期靶点验证到先导化合物筛选,以及耐药性风险的临床前评估的整个发现流程。